Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Fluvoxamine | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Fluvoxamine. |
| Citalopram | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Citalopram. |
| Fluoxetine | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Fluoxetine. |
| Duloxetine | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Duloxetine. |
| Trazodone | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Trazodone. |
| Paroxetine | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Paroxetine. |
| Sertraline | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Sertraline. |
| Sibutramine | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Sibutramine. |
| Nefazodone | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Nefazodone. |
| Escitalopram | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Escitalopram. |
| Zimelidine | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Zimelidine. |
| Dapoxetine | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Dapoxetine. |
| Milnacipran | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Milnacipran. |
| Desvenlafaxine | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Desvenlafaxine. |
| Seproxetine | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Seproxetine. |
| Indalpine | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Indalpine. |
| Ritanserin | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Ritanserin. |
| Alaproclate | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Alaproclate. |
| Pamidronic acid | The risk or severity of hypocalcemia can be increased when Elcatonin is combined with Pamidronic acid. |
| Zoledronic acid | The risk or severity of hypocalcemia can be increased when Elcatonin is combined with Zoledronic acid. |
| Alendronic acid | The risk or severity of hypocalcemia can be increased when Elcatonin is combined with Alendronic acid. |
| Ibandronate | The risk or severity of hypocalcemia can be increased when Elcatonin is combined with Ibandronate. |
| Clodronic acid | The risk or severity of hypocalcemia can be increased when Elcatonin is combined with Clodronic acid. |
| Risedronic acid | The risk or severity of hypocalcemia can be increased when Elcatonin is combined with Risedronic acid. |
| Etidronic acid | The risk or severity of hypocalcemia can be increased when Elcatonin is combined with Etidronic acid. |
| Tiludronic acid | The risk or severity of hypocalcemia can be increased when Elcatonin is combined with Tiludronic acid. |
| Incadronic acid | The risk or severity of hypocalcemia can be increased when Elcatonin is combined with Incadronic acid. |
| Lithium citrate | Elcatonin may increase the excretion rate of Lithium citrate which could result in a lower serum level and potentially a reduction in efficacy. |
| Lithium carbonate | Elcatonin may increase the excretion rate of Lithium carbonate which could result in a lower serum level and potentially a reduction in efficacy. |
| Lithium hydroxide | Elcatonin may increase the excretion rate of Lithium hydroxide which could result in a lower serum level and potentially a reduction in efficacy. |
| Amphetamine | The risk or severity of adverse effects can be increased when Amphetamine is combined with Elcatonin. |
| Phentermine | The risk or severity of adverse effects can be increased when Phentermine is combined with Elcatonin. |
| Midodrine | The risk or severity of adverse effects can be increased when Midodrine is combined with Elcatonin. |
| Norepinephrine | The risk or severity of adverse effects can be increased when Norepinephrine is combined with Elcatonin. |
| Phenylephrine | The risk or severity of adverse effects can be increased when Phenylephrine is combined with Elcatonin. |
| Phenylpropanolamine | The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Elcatonin. |
| Labetalol | The risk or severity of adverse effects can be increased when Labetalol is combined with Elcatonin. |
| Metaraminol | The risk or severity of adverse effects can be increased when Metaraminol is combined with Elcatonin. |
| Epinephrine | The risk or severity of adverse effects can be increased when Epinephrine is combined with Elcatonin. |
| Methoxamine | The risk or severity of adverse effects can be increased when Methoxamine is combined with Elcatonin. |
| Orciprenaline | The risk or severity of adverse effects can be increased when Orciprenaline is combined with Elcatonin. |
| Phenmetrazine | The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Elcatonin. |
| Dobutamine | The risk or severity of adverse effects can be increased when Dobutamine is combined with Elcatonin. |
| Pseudoephedrine | The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Elcatonin. |
| Benzphetamine | The risk or severity of adverse effects can be increased when Benzphetamine is combined with Elcatonin. |
| Ritodrine | The risk or severity of adverse effects can be increased when Ritodrine is combined with Elcatonin. |
| Terbutaline | The risk or severity of adverse effects can be increased when Terbutaline is combined with Elcatonin. |
| Oxymetazoline | The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Elcatonin. |
| Diethylpropion | The risk or severity of adverse effects can be increased when Diethylpropion is combined with Elcatonin. |
| Dopamine | The risk or severity of adverse effects can be increased when Dopamine is combined with Elcatonin. |
| Isoprenaline | The risk or severity of adverse effects can be increased when Isoprenaline is combined with Elcatonin. |
| Acebutolol | The risk or severity of adverse effects can be increased when Acebutolol is combined with Elcatonin. |
| Lisdexamfetamine | The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Elcatonin. |
| Fenoterol | The risk or severity of adverse effects can be increased when Fenoterol is combined with Elcatonin. |
| Ephedrine | The risk or severity of adverse effects can be increased when Ephedrine is combined with Elcatonin. |
| Mephentermine | The risk or severity of adverse effects can be increased when Mephentermine is combined with Elcatonin. |
| Procaterol | The risk or severity of adverse effects can be increased when Procaterol is combined with Elcatonin. |
| Clenbuterol | The risk or severity of adverse effects can be increased when Clenbuterol is combined with Elcatonin. |
| MMDA | The risk or severity of adverse effects can be increased when MMDA is combined with Elcatonin. |
| Midomafetamine | The risk or severity of adverse effects can be increased when Midomafetamine is combined with Elcatonin. |
| 2,5-Dimethoxy-4-ethylamphetamine | The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Elcatonin. |
| 4-Bromo-2,5-dimethoxyamphetamine | The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Elcatonin. |
| Tenamfetamine | The risk or severity of adverse effects can be increased when Tenamfetamine is combined with Elcatonin. |
| Chlorphentermine | The risk or severity of adverse effects can be increased when Chlorphentermine is combined with Elcatonin. |
| Methylenedioxyethamphetamine | The risk or severity of adverse effects can be increased when Methylenedioxyethamphetamine is combined with Elcatonin. |
| Dextroamphetamine | The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Elcatonin. |
| Metamfetamine | The risk or severity of adverse effects can be increased when Metamfetamine is combined with Elcatonin. |
| Celiprolol | The risk or severity of adverse effects can be increased when Celiprolol is combined with Elcatonin. |
| Nylidrin | The risk or severity of adverse effects can be increased when Nylidrin is combined with Elcatonin. |
| Tetryzoline | The risk or severity of adverse effects can be increased when Tetryzoline is combined with Elcatonin. |
| Tyramine | The risk or severity of adverse effects can be increased when Tyramine is combined with Elcatonin. |
| Isoxsuprine | The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Elcatonin. |
| Etilefrine | The risk or severity of adverse effects can be increased when Etilefrine is combined with Elcatonin. |
| Synephrine | The risk or severity of adverse effects can be increased when Synephrine is combined with Elcatonin. |
| Iofetamine I-123 | The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Elcatonin. |
| Racepinephrine | The risk or severity of adverse effects can be increased when Racepinephrine is combined with Elcatonin. |
| Ritobegron | The risk or severity of adverse effects can be increased when Ritobegron is combined with Elcatonin. |
| Bucindolol | The risk or severity of adverse effects can be increased when Bucindolol is combined with Elcatonin. |
| Tramazoline | The risk or severity of adverse effects can be increased when Tramazoline is combined with Elcatonin. |
| Mephedrone | The risk or severity of adverse effects can be increased when Mephedrone is combined with Elcatonin. |
| Fenozolone | The risk or severity of adverse effects can be increased when Fenozolone is combined with Elcatonin. |
| Methoxyphenamine | The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Elcatonin. |
| Tretoquinol | The risk or severity of adverse effects can be increased when Tretoquinol is combined with Elcatonin. |
| Gepefrine | The risk or severity of adverse effects can be increased when Gepefrine is combined with Elcatonin. |
| Epanolol | The risk or severity of adverse effects can be increased when Epanolol is combined with Elcatonin. |
| Prenalterol | The risk or severity of adverse effects can be increased when Prenalterol is combined with Elcatonin. |
| Mefenorex | The risk or severity of adverse effects can be increased when Mefenorex is combined with Elcatonin. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Elcatonin. |
| Gefitinib | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Gefitinib. |
| Sorafenib | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Sorafenib. |
| Erlotinib | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Erlotinib. |
| Imatinib | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Imatinib. |
| Dasatinib | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Dasatinib. |
| Lapatinib | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Lapatinib. |
| Sunitinib | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Sunitinib. |
| Genistein | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Genistein. |
| 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone | The therapeutic efficacy of Elcatonin can be decreased when used in combination with 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone. |
| Geldanamycin | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Geldanamycin. |
| PD173955 | The therapeutic efficacy of Elcatonin can be decreased when used in combination with PD173955. |
| Radicicol | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Radicicol. |